Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

VITAL: Real-World Evaluation of Amlodipine/Valsartan. (VITAL)

24 septembre 2026 mis à jour par: VIVA PHARM LLP

Evaluation of Clinical Effectiveness in Real-World Clinical Practice, as Well as the Safety and Adherence to Therapy With a Fixed-Dose Combination of Amlodipine and Valsartan

The goal of this observational study is to evaluate the effectiveness, safety, and treatment adherence of a fixed-dose combination of amlodipine and valsartan in adults with grade 2-3 hypertension in real-world clinical practice in Kazakhstan. The study will include patients who have already been prescribed the fixed-dose combination of amlodipine and valsartan (Agvistat®) by their treating physician as part of routine medical care, independently of their participation in the study.

The main questions it aims to answer are:

What proportion of participants achieve the target blood pressure after 12 weeks of treatment with the fixed-dose combination of amlodipine and valsartan? How well do participants adhere to treatment, and what patient characteristics are associated with treatment adherence? What changes occur in blood pressure, heart rate, quality of life, and selected laboratory measures during the 12-week observation period? What adverse events occur during treatment?

Participants will:

Have their clinical and demographic information and data from routine medical care recorded during the study.

Have blood pressure, heart rate, and other relevant clinical data assessed during the 12-week observation period.

Complete questionnaires assessing treatment adherence and quality of life. Participate in follow-up visits at 4, 8, and 12 weeks; the 4- and 8-week visits will be conducted remotely, while the enrollment and 12-week visits will be conducted at the study site.

Aperçu de l'étude

Statut

Actif, ne recrute pas

Les conditions

Intervention / Traitement

Type d'étude

Observationnel

Inscription (Réel)

216

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Lieux d'étude

  • Kazakhstan
      • Aktobe, Kazakhstan
        • 'Kuanysh' LLP Health Centre
      • Aktobe, Kazakhstan
        • 'Phoenix Hospital' LLP
      • Aktobe, Kazakhstan
        • Sara Clinic Medical Centre LLP
      • Almaty, Kazakhstan
        • "Medical Assistance Group" LLP
      • Almaty, Kazakhstan
        • 'Vector Vita' Medical Centre LLP
      • Almaty, Kazakhstan
        • State-owned Enterprise for Public Health 'National Hospital of the Medical Centre of the Presidential Administration of the Republic of Kazakhstan'
      • Astana, Kazakhstan
        • "Green Clinic" LLP
      • Astana, Kazakhstan
        • "Kazakhstan Social and Medical Company 'ZHANYA' LLP"
      • Astana, Kazakhstan
        • State-owned Enterprise 'Hospital of the Medical Centre of the Presidential Administration of the Republic of Kazakhstan'
      • Shymkent, Kazakhstan
        • "Clinic DL-ECO" LLP
      • Shymkent, Kazakhstan
        • "Esculap-Vita" LLP
      • Shymkent, Kazakhstan
        • "OrkenMed" LLP
      • Shymkent, Kazakhstan
        • 'Ai-Nury' Medical Centre LLP
      • Ust-Kamenogorsk, Kazakhstan
        • 'GaMMA' Clinical and Diagnostic Centre LLP
      • Ust-Kamenogorsk, Kazakhstan
        • State Communal Enterprise on the Right of Economic Management "East Kazakhstan Regional Hospital
      • Ust-Kamenogorsk, Kazakhstan
        • The 'Outpatient Centre' organisation
    • Turkistan Oblast
      • Shymkent, Turkistan Oblast, Kazakhstan
        • "Medical Center Shubarsu" LLP
      • Turkestan, Turkistan Oblast, Kazakhstan
        • "Clinic of Doctor Irsaliev N.R." LLP

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans et plus (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

Méthode d'échantillonnage

Échantillon non probabiliste

Population étudiée

The study population will consist of adult male and female patients aged ≥18 years with a confirmed diagnosis of grade 2-3 hypertension who have been prescribed a fixed-dose combination of amlodipine and valsartan (Agvistat®) by their treating physician as part of standard clinical practice, independently of participation in the study. The study will include patients with a medical history indicating failure to achieve target blood pressure while receiving a free combination of antihypertensive drugs. A total of 216 participants will be enrolled and observed for up to 12 weeks.

La description

Inclusion Criteria:

  1. Male or female participants aged ≥18 years at the time of enrollment.
  2. Signed and dated written informed consent in accordance with ICH GCP and applicable local legislation before enrollment in the study.
  3. Women of childbearing potential must use an adequate method of contraception throughout the study.
  4. Documented diagnosis of grade 2-3 hypertension according to current clinical guidelines for hypertension, defined as systolic blood pressure (SBP) ≥140 mmHg and/or diastolic blood pressure (DBP) ≥90 mmHg measured at two different visits.
  5. Treatment with a fixed-dose combination of amlodipine and valsartan (Agvistat®) prescribed by the treating physician as part of standard clinical practice before enrollment, independently of participation in this study.
  6. Medical history indicating failure to achieve target blood pressure while receiving a free combination of antihypertensive drugs.

Exclusion Criteria:

  1. Participation in any randomized controlled trial within 3 months before enrollment in this study or during participation in this study.
  2. Atrial fibrillation; severe chronic heart failure (NYHA functional class III-IV or left ventricular ejection fraction ≤40% by echocardiography); or acute coronary syndrome or acute cerebrovascular event within the previous year.
  3. Secondary hypertension.
  4. Contraindications or conditions requiring caution listed in the prescribing information for the fixed-dose combination of amlodipine and valsartan, including: hypersensitivity to the active substances, other dihydropyridine derivatives, or any excipients; severe hepatic impairment, biliary cirrhosis, or cholestasis; concomitant use of aliskiren-containing medicinal products in patients with diabetes mellitus or renal impairment (eGFR <60 mL/min/1.73 m²); second or third trimester of pregnancy; severe hypotension; shock, including cardiogenic shock; left ventricular outflow tract obstruction, including hypertrophic obstructive cardiomyopathy or severe aortic stenosis; and hemodynamically unstable heart failure following acute myocardial infarction.

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Modèles d'observation: COHORT
  • Perspectives temporelles: PROSPECTIVE

Cohortes et interventions

Groupe / Cohorte
Intervention / Traitement
Amlodipine/valsartan-treated cohort

Adults with grade 2-3 hypertension who have been prescribed a fixed-dose combination of amlodipine and valsartan (Agvistat®) by their treating physician as part of routine clinical practice, independently of participation in the study. Participants are observed for up to 12 weeks to assess treatment effectiveness, adherence, safety, blood pressure control, and quality of life.
Médicament: Amlodipine / Valsartan

Fixed-dose combination of amlodipine and valsartan administered as part of routine clinical practice. The treatment is prescribed by the treating physician independently of study participation. The study does not assign treatment or provide the study drug. The available doses are amlodipine 5 mg/valsartan 160 mg and amlodipine 10 mg/valsartan 160 mg, administered once daily.

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Proportion of participants achieving target blood pressure at 12 weeks
Délai: 12 weeks

Proportion of participants who achieve the target blood pressure after 12 weeks of therapy: <140/90 mmHg for the general population or <130/80 mmHg for participants at high cardiovascular risk and participants younger than 60 years.
12 weeks

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Association between treatment adherence and clinical and demographic characteristics
Délai: 12 weeks

Association between treatment adherence, assessed using the Morisky-Green scale, and clinical and demographic characteristics of participants, including age, sex, comorbidities, and duration of hypertension.
12 weeks
Change in heart rate from baseline
Délai: 12 weeks

Change in heart rate from baseline during the observation period.
12 weeks
Change in alanine aminotransferase (ALT) from baseline
Délai: 12 weeks

Change in alanine aminotransferase (ALT) level from baseline during the observation period.
12 weeks
Change in aspartate aminotransferase (AST) from baseline
Délai: 12 weeks

Change in aspartate aminotransferase (AST) level from baseline during the observation period.
12 weeks
Change in serum creatinine from baseline
Délai: 12 weeks

Change in serum creatinine level from baseline during the observation period.
12 weeks
Change in blood glucose from baseline
Délai: 12 weeks

Change in blood glucose level from baseline during the observation period.
12 weeks
Change in low-density lipoprotein cholesterol from baseline
Délai: 12 weeks

Change in low-density lipoprotein cholesterol (LDL-C) level from baseline during the observation period.
12 weeks
Change in body mass index from baseline
Délai: 12 weeks

Change in body mass index (BMI) from baseline during the observation period.
12 weeks
Change in EQ-5D quality of life score
Délai: 12 weeks

Change in the score of the standardized EQ-5D quality of life questionnaire during the observation period.
12 weeks
Association of clinical and demographic factors with achievement of target blood pressure
Délai: 12 weeks

Association of clinical and demographic factors, including diabetes mellitus, obesity, grade of hypertension, chronic heart failure, age, and sex, with achievement of target blood pressure at 12 weeks of therapy.
12 weeks
Patient satisfaction with treatment
Délai: 12 week

Assessment of participants' satisfaction with treatment using a 5-point Likert scale.
12 week
Frequency and characteristics of adverse drug reactions
Délai: 12 weeks

Frequency and characteristics of adverse drug reactions associated with the use of the fixed-dose combination of amlodipine and valsartan, identified based on the analysis of adverse reaction reports (Yellow Cards).
12 weeks

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Parrainer

VIVA PHARM LLP

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

20 novembre 2025

Achèvement primaire (Estimé)

20 septembre 2026

Achèvement de l'étude (Estimé)

20 novembre 2026

Dates d'inscription aux études

Première soumission

14 septembre 2026

Première soumission répondant aux critères de contrôle qualité

24 septembre 2026

Première publication (Réel)

29 septembre 2026

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

29 septembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

24 septembre 2026

Dernière vérification

1 septembre 2026

Plus d'information

Termes liés à cette étude

Mots clés

Termes MeSH pertinents supplémentaires

Autres numéros d'identification d'étude

  • VP-01

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

NON

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner